Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BYGastro hep advances

Ustekinumab for Extraintestinal Manifestations in Patients With Inflammatory Bowel Disease: Lessons From the TENOR Real-World Study.

  • Romain Altwegg1
  • Miceli Corinne2
  • Paul Carle3
  • Sosnowiez Katia4
  • Bessette Christel5
  • Peyrin-Biroulet Laurent6
6 affiliations
  1. 1Department of Gastroenterology, Hôpital Saint-Eloi, CHU de Montpellier, Montpellier, France.
  2. 2Department of Rheumatology, Cochin Hospital, Paris, France.
  3. 3Department of Dermatology, CHU de Toulouse, Toulouse, France.
  4. 4J&J Innovative Medicine, France.
  5. 5ICON plc, Puteaux, France.
  6. 6Department of Gastroenterology, CHRU de Nancy, Vandœuvre-lès-Nancy, France.
Read full textPDFDOICite

Related

  1. Prevalence, timing and risk factors of extraintestinal manifestations in inflammatory bowel disease: a retrospective cohort study from a German tertiary referral center.
    Fotios Fousekis, Panagiotis Garantziotis, André Jefremow +6
    Crohn's & colitis 360Peer-reviewedCC BYFull textGenetics & genomicsEurope PMC
  2. Comparative Safety of Ustekinumab and Vedolizumab in Older Patients with Inflammatory Bowel Disease: A Bicentric Cohort Study
    Alice Burgevin, Bénédicte Caron, Alexa Sasson +5
    Journal of Clinical MedicinePeer-reviewedCC BY 4.0Full text10 citedGenetics & genomicsHAL
  3. Gut–Brain Axis-Mediated Neurological Manifestations in Inflammatory Bowel Disease: Mechanisms and Disease Spectrum
    Bingchan Sun, Guoxin Wang, Xiaoxia Li +7
    Journal of Neurogastroenterology and MotilityPeer-reviewedCC BY-NC 4.0Full textGenetics & genomicsPMC
  4. A real-world study of healthcare resource utilization and costs in patients with Crohn's disease and ulcerative colitis initiating ustekinumab treatment via Johnson & Johnson's BIOADVANCE program.
    Laura Targownik, Eneda Pone, Martin G Latour +6
    Crohn's & colitis 360Peer-reviewedCC BY-NCFull textGenetics & genomicsEurope PMC
  5. Predictive value of NLR,MLR and CAR on the efficacy of ustekinumab in patients with Crohn's disease
    WANG Jing, LI Lin, CHEN Pingbo +2
    Zhongguo linchuang yanjiuPeer-reviewedCC BY-NC-NDFull textGenetics & genomicsDOAJ

Cite

BibTeXRIS
BibTeX
@article{altwegg2026ustekinumab,
  title = {{Ustekinumab for Extraintestinal Manifestations in Patients With Inflammatory Bowel Disease: Lessons From the TENOR Real-World Study.}},
  author = {Romain Altwegg and Miceli Corinne and Paul Carle and Sosnowiez Katia and Bessette Christel and Peyrin-Biroulet Laurent},
  journal = {Gastro hep advances},
  year = {2026},
  month = sep,
  doi = {10.1016/j.gastha.2026.101115},
  url = {https://europepmc.org/article/MED/42904055},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Ustekinumab for Extraintestinal Manifestations in Patients With Inflammatory Bowel Disease: Lessons From the TENOR Real-World Study.
AU  - Romain Altwegg
AU  - Miceli Corinne
AU  - Paul Carle
AU  - Sosnowiez Katia
AU  - Bessette Christel
AU  - Peyrin-Biroulet Laurent
PY  - 2026
DA  - 2026/09/17
JO  - Gastro hep advances
DO  - 10.1016/j.gastha.2026.101115
UR  - https://europepmc.org/article/MED/42904055
SN  - 2772-5723
ER  -